These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34143560)

  • 1. Get use to the -dustats: Roxadustat and molidustat, members of the hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor drug class promote kidney function, perfusion and oxygenation in rats through nitric oxide.
    Jensen BL
    Acta Physiol (Oxf); 2021 Sep; 233(1):e13706. PubMed ID: 34143560
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, on sodium dynamics in hypertensive subtotally nephrectomized rats.
    Zhang A; Nakano D; Morisawa N; Kitada K; Kittikulsuth W; Rahman A; Morikawa T; Konishi Y; Nishiyama A
    J Pharmacol Sci; 2021 Jun; 146(2):98-104. PubMed ID: 33941326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Basis of Prolyl Hydroxylase Domain Inhibition by Molidustat.
    Figg WD; McDonough MA; Chowdhury R; Nakashima Y; Zhang Z; Holt-Martyn JP; Krajnc A; Schofield CJ
    ChemMedChem; 2021 Jul; 16(13):2082-2088. PubMed ID: 33792169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prolyl hydroxylase inhibitor roxadustat: Paradigm in drug discovery and prospects for clinical application beyond anemia.
    Su K; Li Z; Yu Y; Zhang X
    Drug Discov Today; 2020 Jul; 25(7):1262-1269. PubMed ID: 32380083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolyl-hydroxylase inhibitors reconstitute tumor blood vessels in mice.
    Nishide S; Uchida J; Matsunaga S; Tokudome K; Yamaguchi T; Kabei K; Moriya T; Miura K; Nakatani T; Tomita S
    J Pharmacol Sci; 2020 Jun; 143(2):122-126. PubMed ID: 32199747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a prolyl hydroxylase inhibitor on kidney and cardiovascular complications in a rat model of chronic kidney disease.
    Uchida L; Tanaka T; Saito H; Sugahara M; Wakashima T; Fukui K; Nangaku M
    Am J Physiol Renal Physiol; 2020 Feb; 318(2):F388-F401. PubMed ID: 31841388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, in chronic kidney disease-associated anemia in cats.
    Charles S; Süssenberger R; Settje T; Langston C; Lainesse C
    J Vet Intern Med; 2024; 38(1):197-204. PubMed ID: 37740521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIF-α activation by the prolyl hydroxylase inhibitor roxadustat suppresses chemoresistant glioblastoma growth by inducing ferroptosis.
    Su X; Xie Y; Zhang J; Li M; Zhang Q; Jin G; Liu F
    Cell Death Dis; 2022 Oct; 13(10):861. PubMed ID: 36209275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological HIF-PHD inhibition reduces renovascular resistance and increases glomerular filtration by stimulating nitric oxide generation.
    Burmakin M; Fasching A; Kobayashi H; Urrutia AA; Damdimopoulos A; Palm F; Haase VH
    Acta Physiol (Oxf); 2021 Sep; 233(1):e13668. PubMed ID: 33900001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mononuclear phagocytes orchestrate prolyl hydroxylase inhibition-mediated renoprotection in chronic tubulointerstitial nephritis.
    Schley G; Klanke B; Kalucka J; Schatz V; Daniel C; Mayer M; Goppelt-Struebe M; Herrmann M; Thorsteinsdottir M; Palsson R; Beneke A; Katschinski DM; Burzlaff N; Eckardt KU; Weidemann A; Jantsch J; Willam C
    Kidney Int; 2019 Aug; 96(2):378-396. PubMed ID: 31146971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for the Capability of Roxadustat (FG-4592), an Oral HIF Prolyl-Hydroxylase Inhibitor, to Perturb Membrane Ionic Currents: An Unidentified yet Important Action.
    Chang WT; Lo YC; Gao ZH; Wu SN
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
    Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
    J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of post-renal anemia treatment with the HIF-PHD inhibitor molidustat on adenine-induced renal anemia and kidney disease in mice.
    Li L; Nakano D; Zhang A; Kittikulsuth W; Morisawa N; Ohsaki H; Suzuki N; Yamamoto M; Nishiyama A
    J Pharmacol Sci; 2020 Dec; 144(4):229-236. PubMed ID: 33070842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
    Gupta N; Wish JB
    Am J Kidney Dis; 2017 Jun; 69(6):815-826. PubMed ID: 28242135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whether Prolyl Hydroxylase Blocker-Roxadustat-In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future?
    Grzeszczak W; Szczyra D; Śnit M
    Int J Environ Res Public Health; 2021 Feb; 18(4):. PubMed ID: 33567688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roxadustat in the treatment of anaemia in chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Investig Drugs; 2018 Jan; 27(1):125-133. PubMed ID: 29254377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stabilizing HIF to Ameliorate Anemia.
    Voit RA; Sankaran VG
    Cell; 2020 Jan; 180(1):6. PubMed ID: 31951520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury.
    Yang Y; Yu X; Zhang Y; Ding G; Zhu C; Huang S; Jia Z; Zhang A
    Clin Sci (Lond); 2018 Apr; 132(7):825-838. PubMed ID: 29581249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications.
    Kim SY; Yang EG
    Molecules; 2015 Nov; 20(11):20551-68. PubMed ID: 26610437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor.
    Kiriakidis S; Hoer SS; Burrows N; Biddlecome G; Khan MN; Thinnes CC; Schofield CJ; Rogers N; Botto M; Paleolog E; Maxwell PH
    Kidney Int; 2017 Oct; 92(4):900-908. PubMed ID: 28506759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.